All In Biotech

Free tool

FAERS Monitor: Doptelet

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210238 or its brand name (Doptelet, Avatrombopag Maleate). Reports on generic versions are filed under their own applications.

Reports

2,368

Serious

839

35% of reports

Hospitalization

421

Death reported

138

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • platelet count decreased420
  • drug ineffective333
  • headache252
  • platelet count increased217
  • fatigue189
  • nausea123
  • product dose omission issue118
  • platelet count abnormal117
  • off label use116
  • death95
  • diarrhoea89
  • inappropriate schedule of product administration82
  • arthralgia79
  • product use issue71
  • dizziness70

Reports by year received

View as table
YearReports
20131
20151
201864
2019106
2020269
2021265
2022237
2023282
2024315
2025375
2026453

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,791 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
platelet count abnormalSignal117175.3146.619,718
platelet count increasedSignal217150.3132.331,529
platelet count decreasedSignal42035.132.213,910
inappropriate schedule of product administrationSignal824.03.3186
headacheSignal2523.63.2478
product dose omission issueSignal1183.63.0218
product use issueSignal713.42.7116
drug ineffectiveSignal3332.22.0244
fatigueSignal1892.21.9120
arthralgia791.71.422
nausea1231.41.213
dizziness701.21.03
diarrhoea891.21.04
off label use1161.21.03
death951.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.